Clinical Trial

Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma

Name: Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma — clinical trial record (NCT06580223)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The aim of this study is to evaluate the efficacy and safety of aspirin and rivaroxaban in thromboprophylaxis in Chinese MM patients at high risk for MM-associated VTE.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2024-08-28; most recent amendment 2025-07-17.

Trial Details

NCT Number	NCT06580223
Lead Sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions	Multiple Myeloma, Venous Thromboembolism
Enrollment	530 participants
Start Date	2025-09-01
Primary Completion	2027-09-01 (estimated)
Study Completion	2027-09-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-18